Create Medic Co., Ltd. Stocks

¥ 1202Last Updated 16.04.2026

Issuer Rating

5/7
Performance

Strong

Risk

Considerable

Recommendation

Hold

Market Cap

¥ 64.45M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
¥ 1202
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Create Medic Co., Ltd. researches, develops, manufactures, and sells medical appliances in Japan and internationally. The company offers disposable medical devices made of silicone resin. It provides various urology, gastroenterology, percutaneous endoscopic gastrostomy, and surgery products. The company also provides other products, such as CLINY tracheostomy tubes, endotracheal tubes, tracheostomy tubes, and microcatheters. In addition, it offers OEM products comprising multi-lumen tubes, ultrathin walls, profile extrusions, and special structures; special shape and high-volume low-pressure cuff moldings; and hydrophilic coating and needles, as well as the technology on an OEM basis. The company was formerly known as NASK Co., Ltd. and changed its name to Create Medic Co., Ltd. in July 1977. Create Medic Co., Ltd. was incorporated in 1974 and is headquartered in Yokohama, Japan.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, 'cheap'

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks